Bioxytran, Inc. Announces the Reinitiation of Coverage of Its Stock by Avise Analytics

Rhea-AI Summary

BIOXYTRAN, INC. (OTCQB: BIXT), a clinical stage biotech firm, has announced that Avise Analytics has reinitiated coverage of its stock, setting a fair valuation at $2.71 per share. The report highlights Bioxytran's ProLectin-M, which shows promising recovery rates for Covid-19 patients and targets a multi-billion-dollar market. Additionally, the company is advancing BXT-25 for stroke treatment, addressing the critical treatment window challenge. Despite positive developments, funding limitations could impact drug development timelines. More details can be found in the full report.

Positive

• ProLectin-M shows 100% recovery for mild-to-moderate Covid-19 patients by day 7.
• ProLectin-M targets a market of over 10 million patients, indicating significant revenue potential.
• BXT-25 overcomes the 3-hour treatment window challenge for stroke victims, enhancing market opportunity.
• Strong management led by Dr. David Platt, who has a history of successful drug development and significant investor returns.

Negative

• Funding limitations may delay the clinical processes for both ProLectin-M and BXT-25.

BOSTON, MASSACHUSETTS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia, announces the reinitiation of coverage of its stock by Avise Analytics, a leading equity research firm specializing in micro-cap and small-cap public companies research, giving a fair valuation of $2.71 per share.

The full research report is available here. Highlights from the report include:

ProLectin-M: Potential Game Changer for Covid-19

Bioxytran is developing niche therapeutics in the crowded Covid-19 antiviral drug space, setting a new benchmark with 100% of patients in mild-to-moderate condition recovering by day 7 and 88% of patients by day 3. ProLectin-M may have significant safety, efficacy, and dosing advantages over currently marketed therapies in its class. The targeted virus types represent an addressable market of over 10 million patients and a multi-billion-dollar market.

Overcoming the Biggest Challenge in Stroke Treatment

The Company continues to focus on developing BXT-25, the only ambulatory treatment which can overcome the problem of a minuscule 3-hour treatment window available for victims of stroke. The Company is not only on an accelerated pathway for the approval of its drug from the FDA but also poised to capture a majority share of the multibillion-dollar global stroke market.

Proven Track Record of Dr. David Platt

With Dr. David Platt, an expert in carbohydrate chemistry with a decade-long management experience, at its helm, Bioxytran is on an accelerated path to emulating his earlier successes. Dr. Platt’s various achievements include a portfolio of patents, the distinction of uplisting two companies from OTC to NASDAQ and creating a value of nearly $1 billion for investors through three publicly traded companies.

INVESTMENT VIEW:

While Covid-19 continues to remain a threat, the unavailability of 100% effective vaccines or antiviral therapeutics offers significant scope for new entrants with significant clinical trial innovation. Positive results from the upcoming Phase III trial of ProLectin-M could position the drug to capture significant market share. However, the inability to garner sufficient funds for the drug development process may delay the clinical process of both Prolectin-M and BXT-25. We are attracted to its strong management team and unique breakthrough technology. We adopt DCF methodology to arrive at a fair valuation of $2.71/share, discounted at a WACC of 12.1%.

About Bioxytran, Inc.

Bioxytran Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, ProLectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran's other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com

To learn more, visit our website: http://www.Bioxytraninc.com

Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com

About Avise Analytics 

Avise Analytics Private Limited (‘Avise Analytics’) is the fastest growing equity research firm that authors institutional quality equity research reports, with special focus on Nano-Cap and Micro-Cap companies that are undervalued and lacks adequate coverage. Avise Analytics is an approved research contributor on premier institutional investor platforms including Thomson Reuters, Factset, and CapitalIQ.

For more information, visit www.aviseanalytics.com 

Disclosures: For full disclosures pertaining to this report, click here

Contact:
Avise Analytics Private Limited
research@aviseanalytics.com 

FAQ

What is the current stock valuation for Bioxytran (BIXT) according to Avise Analytics?

Avise Analytics has set a fair valuation of $2.71 per share for Bioxytran (BIXT).

What are the recovery rates for patients using ProLectin-M for Covid-19?

ProLectin-M has shown a 100% recovery rate for mild-to-moderate Covid-19 patients by day 7, and 88% by day 3.

What innovative solution is Bioxytran developing for stroke treatment?

Bioxytran is developing BXT-25, the only ambulatory treatment that addresses the crucial 3-hour treatment window for stroke patients.

What challenges does Bioxytran face in drug development?

Bioxytran faces funding limitations that may delay the clinical development process of its drug candidates ProLectin-M and BXT-25.